Affordable Access

Publisher Website

Novel trial designs: which agents and how do we test them?

Authors
Journal
Urology
0090-4295
Publisher
Elsevier
Publication Date
Volume
60
Issue
3
Identifiers
DOI: 10.1016/s0090-4295(02)01587-x
Disciplines
  • Design
  • Medicine

Abstract

Abstract Over the last decade, an increasing number of novel therapies have been tested in prostate cancer. Although each agent has potential to affect the natural history of the disease, how we should proceed, select, and test these agents to show a clinical benefit remains a dilemma. Because prostate cancer is a heterogeneous disease, an understanding of the disease states is required to screen and test novel agents. Only with the appropriate selection of disease state, trial design, and endpoints will we be able to select the most promising regimens to move forward.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

What clinical trial designs have been used to test...

on Epileptic disorders : internat... June 2012

Test cells: Do we need them?

on Building and Environment Jan 01, 1993

Field trials of tuberculosis vaccines: how could w...

on Controlled clinical trials August 1994
More articles like this..